Navigation Links
Ancient Viral Defense may Explain Susceptibility to HIV: Study

A gene that protected man from an ancient retrovirus that infected chimps and other primates millions of years ago may be one reason why our species is susceptible to HIV, said a study released Thursday. The gene appears to have been instrumental in protecting man against a four-million-year-old virus, called Pan troglodytes endogenous retrovirus, or PtERV1.

The virus is now extinct, but like most retroviruses, it inserts its DNA into the genome of organisms it infects, and it left its fingerprints all over the chimpanzee genome.

In fact, when the chimp genome was sequenced in 2005, it emerged that the largest difference between chimp and human DNA was the presence of PtERV1. Researchers at the Fred Hutchinson Cancer Research Center in Seattle, Washington, were intrigued by the disparity and speculated that the reason the virus had not left any markers in the human genome was because of an antiviral defense gene called TRIM5a.

"We know that PtERV1 infected chimps, gorillas and old world monkeys four million years ago but left no traces of having infected humans. Our theory is that this is because humans had this innate viral defense system," said Michael Emerman, a virologist at the center. To test their theory, Emerman and his team painstakingly reconstructed a small portion of the PtERV1 virus using DNA sequences from the chimp genome, and in laboratory experiments with human cells, matched it up with the human antiviral protein TRIM5a.

The TRIM5a neutralized the partial virus but when the investigators re-engineered the protein to make it more effective against HIV, a modern-day retrovirus, the changes inhibited the protein's ability to stop PtERV1 and vice versa. This suggests that the antiviral gene may only be good at fighting off one virus at a time, according to the authors of the study in the journal Science.

"TRIM5a may have served humans well millions of years ago, the antiviral protei
'"/>




Page: 1 2

Related medicine news :

1. Respecting Dwarfs- A Lesson To Be Learnt From Ancient Egyptians
2. A Plant Used By Ancient Britons Found To Have Properties To Fight Cancer
3. Mining of Ancient Herbal Text Leads to Potential New Anti-Bacterial Drug
4. Ancient Herbal Text Paves the Way to Novel Anti-bacterial Drug
5. Mining of Ancient Herbal Text Leads to Potential New Anti-Bacterial Drug
6. Ancient Genes Used to Produce Salt-Tolerant Wheat
7. Ancient Worm Disease Could Be Eradicated Within Two Years, UN Agency Reports
8. Ancient Indian Herb May Prove Cure For Recurrent UTI
9. Ancient Healing Technique Gains New Popularity in Iraq
10. Ancient Ancestors Might Have Had a Clue to HIV
11. Viral encephalitis can cause more damage than already known
Post Your Comments:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 1The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 2The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 1Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 2Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 4Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 5AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4